Immune checkpoint blockade (ICB) is limited by redundant immunosuppressive pathways and the non-immunogenic cold state of solid tumors. Here we develop a biomimetic nanodepot (mFeA-MIP) with a mesoporous Fe3O4 core and a dual-template molecularly imprinted polymer shell targeting CD47 and Galectin-3 (Gal-3) epitopes.